Gene therapy for progressive muscular dystrophy using a new generation adenovirus vector (gutless adenovirus)
使用新一代腺病毒载体(无肠腺病毒)治疗进行性肌营养不良症
基本信息
- 批准号:15590897
- 负责人:
- 金额:$ 2.24万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (C)
- 财政年份:2003
- 资助国家:日本
- 起止时间:2003 至 2004
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The helper-dependent adenovirus(HDAd) vector is less immunogenic and has a larger cloning capacity of up to 37 kb enough to carry the full-length dystrophin cDNA. However, high and long-term expression of dystrophin transduced to mature muscle still remains difficult. One of the main reasons for this is that the expression of the Coxsakievirus and adenovirus receptor(CAR) is very low in mature muscle. We have constructed two different HDAd vectors. One contains the LacZ and the murine full-length dystrophin expression cassette(HDAdLacZ-dys), and the other is a new, improved vector containing the CAR and the dystrophin expression cassette(HDAdCAR-dys). We initially demonstrated high dystrophin expression and prevention of the dystrophic pathology in mdx muscle injected during the neonatal phase with HDAdLacZ-dys. Furthermore, we demonstrated that repeated injections of HDAdCAR-dys into mature muscle led to approximately nine times greater dystrophin-positive fibers in number than a single injection, thereby recovering the expression of dystrophin-associated proteins. This data has also shown that HDAdCAR-dys enabled administration of adenovirus(Ad) vector to the host with pre-existing immunity to the same serotype of Ad. Repetitive injections of the HDAd vector containing the CAR and the dystrophin expression cassette could improve the efficiency of subsequent dystrophin gene transfer to mature mdx muscle. This result suggests that our new HDAd vector will provide a novel gene therapy strategy for Duchenne muscular dystrophy, raising the prospects for gene therapy of other hereditary myopaties.
辅助依赖型腺病毒(HDAd)载体的免疫原性较弱,克隆能力较大,可达37kb,足以携带全长dystrophin基因。然而,转导到成熟肌肉的dystrophin的高和长期表达仍然是困难的。其中一个主要原因是柯萨基病毒和腺病毒受体(CAR)在成熟肌肉中的表达很低。我们构建了两个不同的HDAd载体。一个包含LacZ和小鼠全长dystrophin表达盒(HDAdLacZ-dys),另一个是包含CAR和dystrophin表达盒的新的改进载体(HDAdCAR-dys)。我们最初证明,在新生儿期注射HDAdLacZ-dys的MDX肌肉中,dystrophin的高表达和营养不良病理的预防。此外,我们还证明,在成熟肌肉中重复注射HDAdCAR-dys后,dystrophin阳性纤维的数量大约是单次注射的九倍,从而恢复了dystrophin相关蛋白的表达。这一数据还表明,HDAdCAR-dys能够将腺病毒(Ad)载体接种到对同一血清型Ad预先存在免疫力的宿主。重复注射含有CAR和dystrophin表达框的HDAd载体可以提高随后将dystrophin基因转移到成熟MDX肌肉的效率。这一结果表明,我们的新HDAd载体将为Duchenne肌营养不良症提供一种新的基因治疗策略,为其他遗传性近视的基因治疗提供前景。
项目成果
期刊论文数量(11)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Maeda Y., Uchino M.et al.: "Cre/lox P-mediated adenovirus type 5 packaging signal excision demonstrates that core element VI is sufficient for virus packaging"Virology. 309. 330-338 (2003)
Maeda Y.、Uchino M.等人:“Cre/lox P 介导的腺病毒 5 型包装信号切除表明核心元件 VI 足以进行病毒包装”病毒学。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Effective repetitive dystrophin gene transfer into skeletal muscle of adult mdx mice using a helper-dependent adenovirus vector expressing the Coxsackie-virus and adenovirus receptor (CAR) and dystrophin.
使用表达柯萨奇病毒和腺病毒受体 (CAR) 和肌营养不良蛋白的辅助依赖性腺病毒载体,将肌营养不良蛋白基因有效重复转移到成年 mdx 小鼠的骨骼肌中。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:Uchida Y.;Maeda Y;Kimura E;Yamashita S;Nishida Y;Arima T;Hirano T;Uyama E;Mita S.;Uchino M.
- 通讯作者:Uchino M.
Effective repetitive dystrophin gene transfer into skeletal muscle of adult mdx mice using a helper-dependent adenovirus vector expressing the Coxsackievirus and adenovirus receptor(CAR) and dystrophin.
使用表达柯萨奇病毒和腺病毒受体 (CAR) 和肌营养不良蛋白的辅助依赖性腺病毒载体,将肌营养不良蛋白基因有效重复转移到成年 mdx 小鼠的骨骼肌中。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:Uchida Y.;Maeda Y;Kimura E;Yamashita S;Nishida Y;Arima T;Hirano T;Uyama E;Mita S.;Uchino M.
- 通讯作者:Uchino M.
Myopathy phenotype in transgenic mice expressing mutated PABPN1 as a model of oculopharyngeal muscular dystrophy
- DOI:10.1093/hmg/ddh017
- 发表时间:2004-01-15
- 期刊:
- 影响因子:3.5
- 作者:Hino, H;Araki, K;Yamamura, K
- 通讯作者:Yamamura, K
Targeted conversion of the transthyretin gene in vitro and in vivo
- DOI:10.1038/sj.gt.3302228
- 发表时间:2004-05-01
- 期刊:
- 影响因子:5.1
- 作者:Nakamura, M;Ando, Y;Yamamura, K
- 通讯作者:Yamamura, K
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
UCHIN Makoto其他文献
UCHIN Makoto的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Clinical application of boron-conjugated adenovirus vector for neutron capture therapy
硼缀合腺病毒载体中子捕获治疗的临床应用
- 批准号:
19K09482 - 财政年份:2019
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Vascular-targeted gene therapy to block proliferation of smooth muscle cells using a novel adenovirus vector
使用新型腺病毒载体进行血管靶向基因治疗以阻止平滑肌细胞增殖
- 批准号:
2273599 - 财政年份:2019
- 资助金额:
$ 2.24万 - 项目类别:
Studentship
Gene therapy for diabetes mellitus based on the suppression of lipotoxicity using an improved adenovirus vector
使用改进的腺病毒载体抑制脂毒性的糖尿病基因治疗
- 批准号:
18K14964 - 财政年份:2018
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mechanisms of induction of mucosal immunity by adenovirus vector vaccine
腺病毒载体疫苗诱导粘膜免疫的机制
- 批准号:
16K18873 - 财政年份:2016
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Hemophilia B Gene Therapy via CRISPR/Cas9-Targeted Integration of the Factor IX Gene using Adenovirus Vector Delivery
使用腺病毒载体递送通过 CRISPR/Cas9 靶向整合因子 IX 基因进行 B 型血友病基因治疗
- 批准号:
9193681 - 财政年份:2016
- 资助金额:
$ 2.24万 - 项目类别:
Gene therapy for diabetes mellitus and gene function analysis using a novel adenovirus vector
使用新型腺病毒载体进行糖尿病基因治疗和基因功能分析
- 批准号:
15K18939 - 财政年份:2015
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Innate immue response through glycolipids by adenovirus-vector
腺病毒载体通过糖脂产生先天免疫反应
- 批准号:
26450450 - 财政年份:2014
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of targeting adenovirus vector as boron carrier for boron neutron capture therapy
开发靶向腺病毒载体作为硼中子捕获疗法的硼载体
- 批准号:
26462183 - 财政年份:2014
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of a novel method for highly efficient gene targeting by adenovirus vector on human naive pluripotent stem cells
开发一种通过腺病毒载体高效基因靶向人类幼稚多能干细胞的新方法
- 批准号:
26893253 - 财政年份:2014
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
Development of adenovirus vector lacking VA RNA genes for efficient microRNA expression
开发缺乏 VA RNA 基因的腺病毒载体以实现有效的 microRNA 表达
- 批准号:
24701021 - 财政年份:2012
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Young Scientists (B)